natgillin/translations-raw huggingface dataset:
In the absence of clinical experience in such patients population, no recommendations on dosage adjustment can be made.
Ker ni kliničnih izkušenj s to populacijo bolnikov, ni mogoče priporočiti prilagoditve odmerka.
In the absence of clinical studies, caution should be exercised in patients with hepatic impairment.
Kliničnih študij niso izvedli, zato je pri bolnikih z jetrno okvaro potrebna previdnost.
In the absence of clinical symptoms, liver transaminases should be monitored at Months 1, 3, 6, 9 and 12 on therapy and periodically thereafter.
Če bolnik nima kliničnih simptomov, je treba koncentracije jetrnih aminotransferaz določiti po 1, 3, 6, 9 in 12 mesecih zdravljenja in periodično tudi kasneje.
In the absence of compatability studies, this medicinal product must not be mixed with other medicinal products.
V odsotnosti študij kompatibilnosti zdravila ne smemo mešati z drugimi zdravili.
In the absence of compatibility studies, do not mix with any other veterinary medicinal product except the solvent supplied for use with the vaccine.
Zaradi pomanjkanja študij kompatibilnosti tega zdravila ne smemo mešati z drugimi zdravili za uporabo v veterinarski medicini, razen z vehiklom, ki je priložen za uporabo s tem cepivom.
In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.
Ker študij kompatibilnosti ni, se zdravila ne sme mešati z drugimi zdravili.
In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.
Zaradi pomanjkanja študij kompatibilnosti zdravila ne smemo mešati z drugimi zdravili..
In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.
Zaradi pomanjkanja študij o kompatibilnosti zdravila ne smete mešati z drugimi zdravili.
In the absence of compatibility studies, this veterinary medicinal product must be reconstituted only with the solvent provided and should not be mixed with other solvents or other veterinary medicinal products.
Zaradi pomanjkanja študij kompatibilnosti tega zdravila ne smemo mešati z drugimi zdravili za uporabo v veterinarski medicini, razen z vehiklom, ki je priložen za uporabo s tem zdravilom.
In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other medicinal products.
Zaradi pomanjkanja študij kompatibilnosti tega zdravila za uporabo v veterinarski medicini ne smemo mešati z drugimi zdravili.
In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products
Zaradi pomanjkanja študij kompatibilnosti tega zdravila ne smemo mešati z drugimi zdravili za uporabo v veterinarski medicine.
In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.
Tega zdravila za uporabo v veterinarski medicini se ne sme dajati z ostalimi zdravili za uporabo v veterinarski medicini, ker nimamo raziskav o kompatibilnosti teh zdravil.
In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.
To zdravilo za uporabo v veterinarski medicini se ne sme dajati z ostalimi zdravili za uporabo v veterinarski medicini, ker nimamo raziskav o kompatibilnosti teh zdravil.
In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.
Zaradi odsotnosti kompatibilnih študij tega zdravila za uporabo v veterinarski medicini ne mešajate z nobenim drugim zdravilom.
In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.
Zaradi odsotnosti študij o kompatibilnosti se to zdravilo ne sme mešati z drugimi zdravili.
In the absence of compatibility studies, this veterinary medicinal product should not be mixed with other veterinary medicinal products.
Ker ni študij o kompatibilnosti, tega zdravila za uporabo v veterinarski medicini ne smemo mešati z drugimi zdravili za uporabo v veterinarski medicini.
In the absence of conventional susceptibility breakpoints for the nebulised route of administration, caution must be exercised in defining organisms as susceptible or insusceptible to nebulised tobramycin.
Ker pri vnosu zdravila s pomočjo nebulatorja ni na voljo običajnih mejnih vrednosti za občutljivost bakterij, je potrebna previdnost pri opredelitvi, kateri organizmi so občutljivi oziroma neobčutljivi na tobramicin, vnesen s pomočjo nebulatorja.
In the absence of data regarding potential interaction with NSAIDs having longer half-lives such as piroxicam or rofecoxib, the concomitant administration with pemetrexed in patients with mild to moderate renal insufficiency should be interrupted for at least 5 days prior to, on the day of, and at least 2 days following pemetrexed administration (see section 4.4).
Ker ni podatkov o možnem medsebojnem delovanju pemetrekseda in NSAID-ov z daljšimi razpolovnimi časi, denimo, piroksikama ali rofekoksiba, moramo sočasno dajanje NSAID-ov s pemetreksedom pri bolnikih z blagim do zmernim popuščanjem delovanja ledvic prekiniti vsaj za dni pred dajanjem pemetrekseda, na dan dajanja in še vsaj za 2 dni po dajanju pemetrekseda (glejte poglavje 4.4).
In the absence of data regarding potential interaction with NSAIDs having longer half-lives such as piroxicam or rofecoxib, the concomitant administration with pemetrexed in patients with mild to moderate renal insufficiency should be interrupted for at least 5 days prior to, on the day of, and at least 2 days following pemetrexed administration (see section 4.4).
Ker ni podatkov o možnem medsebojnem delovanju pemetrekseda in NSAID-ov z daljšimi razpolovnimi časi, denimo, piroksikama ali rofekoksiba, se moramo sočasno dajanje NSAID-ov s pemetreksedom pri bolnikih z blagim do zmernim popuščanjem delovanja ledvic prekiniti vsaj za 5 dni pred dajanjem pemetrekseda, na dan dajanja in še vsaj za 2 dni po dajanju pemetrekseda (glejte poglavje 4.4).
In the absence of data, administration of the product is not recommended to infants with hepatic or renal impairment (see section 4.4).
Zaradi pomanjkanja podatkov dajanje zdravila ni priporočljivo za dojenčke z motnjami delovanja jeter ali ledvic (glejte poglavje 4.4).
In the absence of functional BRCA1 or 2, DNA DSBs cannot be repaired via HRR.
Če funkcionalnih BRCA 1 ali 2 ni, homologno popravljanje z rekombinacijo ne more popraviti dvoverižnih prekinitev DNA.
In the absence of human data, it is not recommended to use Resolor during breast-feeding.
Zaradi pomanjkanja podatkov pri ljudeh zdravila Resolor ni priporočljivo uporabljati med dojenjem.
In the absence of human data, Oprymea should not be used during breast-feeding.
Zdravilo Oprymea ne dajemo doječim materam, zaradi pomanjkanja podatkov.
In the absence of incompatibility studies, this medicinal product must not be mixed or administered as an infusion with other medicinal products.
Zaradi pomanjkanja študij kompatibilnosti tega zdravila ne smete mešati ali aplicirati v infuziji z drugimi zdravili.
In the absence of incompatibility studies, this medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.
Zaradi odsotnosti študij inkompatibilnosti tega zdravila ne smete mešati z drugimi zdravili, razen s tistimi, navedenimi v poglavju 6.6.
In the absence of incompatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.
Zaradi pomanjkanja študij kompatibilnosti tega zdravila ne smemo mešati z drugimi zdravili.
In the absence of information on the specific P450 isoenzymes involved, caution should be taken when co-prescribing active substances metabolised by this route such as, among others, anticonvulsants, rifabutin, rifampicin, griseofulvin and St. John’s wort (Hypericum perforatum).
Ker ni poznano, kateri izoencimi P450 so vpleteni, je potrebna pazljivost pri sočasnem predpisovanju zdravilnih učinkovin, ki se presnavljajo po tej poti, med drugim tudi antikonvulzivov, rifabutina, rifampicina, grizeofulvina in šentjanževke (Hypericum perforatum).
In the absence of information, it is recommended not to apply other topical preparations simultaneously on the same lesions.
Ker ni podatkov , odsvetujemo sočasno uporabljanje drugih površinskih preparatov za zdravljenje istih ran.
In the absence of information, it is recommended not to apply other topical preparations simultaneously on the same lesions.
Ker podatkov o tem ni, odsvetujemo sočasno uporabljanje tega zdravila in drugih zdravil za lokalno uporabo za zdravljenje istih poškodb.
In the absence of premedication, inhaled concentrations of sevoflurane in the range 3.7 to 3.8% will provide surgical levels of anaesthesia in the healthy dog.
Če premedikacije ni, bodo inhalirane koncetracije sevoflurana v mejah 3,7 do 3,8 % pri zdravem psu povzročile kirurške ravni anestezije.
In the absence of risk of co-infestation, the use of a narrow spectrum parasiticide should be considered as a first line therapy.
V primeru, da ni nevarnosti za tako koinfestacijo, je potrebno kot zdravilo prvega izbora uporabiti paraziticid z ožjim spektrom delovanja.
In the absence of specific clinical data in patients with impaired hepatic or renal function, stiripentol is not recommended for use in patients with impaired hepatic and/or renal function.
Zaradi pomanjkanja specifičnih kliničnih podatkov o bolnikih z okvarjenim delovanjem jeter ali ledvic uporaba stiripentola pri teh bolnikih ni priporočljiva.
In the absence of specific information, the use in animal suffering from Cushing’s syndrome shall be based on the risk-benefit assessment.
Zaradi pomanjkanja specifičnih podatkov, se živali, ki imajo Cushingov sindrom, zdravi v skladu z oceno razmerja korist/tveganje.
In the absence of specific information, the use in animal suffering from Cushing’s syndrome shall be based on the risk-benefit assessment.
Če ne razpolagamo s specifičnimi podatki, se živali, ki imajo Cushingov sindrom, Zdravi v skladu z oceno razmerja korist/tveganje.
In the absence of specific studies, ellaOne is not recommended.
Zaradi pomanjkanja specifičnih študij se uporaba zdravila ellaOne ne priporoča.
In the absence of specific studies, no alternate dose recommendations for ellaOne can be made.
Zaradi pomanjkanja specifičnih študij za zdravilo ellaOne ni mogoče podati priporočil za drugačno odmerjanje.
In the absence of specific studies, no other veterinary medicinal product should be administered concurrently with the product.
Ker ni podatkov posebnih raziskav, odsvetujemo sočasno uporabo tega cepiva z drugimi zdravili za uporabo v veterinarski medicini z in ovo načinom vnosa.
In the absence of specific studies, ulipristal acetate is not recommended in patients with moderate or severe hepatic impairment unless the patient is closely monitored (see sections 4.4 and 5.2).
Specifičnih študij niso opravili, zato uporaba ulipristalacetata pri bolnicah z zmerno ali hudo jetrno okvaro ni priporočljiva, razen, če bolnico pozorno spremljate (glejte poglavji 4.4 in 5.2).
In the absence of the 6 mg/ml oral suspension formulation, the pharmacy compounded preparation should preferentially be used.
V primeru, da 6 mg/ml peroralna suspenzija ni na voljo, se mora preferenčno uporabiti v lekarni pripravljen izdelek.
In the AC-052-352 study, 92% of the 213 patients were classified at baseline as WHO functional class III and 8% as class IV.
V študiji AC-052-352 so 92 % od 213 bolnikov izhodiščno opredelili v funkcijski razred III po klasifikaciji SZO, 8 % pa v razred IV.
In the active treatment arm, Xtandi was administered orally at a dose of 160 mg daily.
V kraku zdravljenja z zdravilno učinkovino so zdravilo Xtandi dajali peroralno v odmerkih po 160 mg na dan.
In the active treatment arm, ZYTIGA was administered at a dose of 1,000 mg daily in combination with low dose prednisone or prednisolone 5 mg twice daily.
Bolniki v skupini z aktivnim zdravljenjem so prejemali zdravilo ZYTIGA v odmerku 1.000 mg na dan v kombinaciji z nizkimi odmerki prednizona ali prednizolona 5 mg dvakrat na dan.
In the active-controlled clinical study conducted in Europe, silodosin 8 mg once daily was shown to be non inferior to tamsulosin 0.4 mg once daily: the adjusted mean difference (95 % CI) in the IPSS Total Score between treatments in the per-protocol population was 0.4 (-0.4 to 1.1).
V z zdravilno učinkovino nadzorovani klinični študiji, izpeljani v Evropi, se je pokazalo, da 8 mg silodozina enkrat na dan ni dajalo slabših rezultatov od 0,4 mg tamsulozina enkrat na dan: prilagojena povprečna razlika (95% CI) v rezultatu vprašalnika IPSS med posameznimi s protokolom določenimi populacijami je znašala 0,4 (-0,4 do 1,1).
In the active-controlled study (the DECIDE study), 919 patients received Zinbryta (150 mg, every 4 weeks) and 922 patients received interferon beta-1a intramuscular, (30 microgram weekly) for a minimum of 2 years and up to 3 years.
V študiji, nadzorovani z zdravilno učinkovino (študija DECIDE), je vsaj 2 leti in največ 3 leta 919 bolnikov prejemalo zdravilo Zinbryta (150 mg, vsake 4 tedne), 922 bolnikov pa je prejemalo interferon beta-1a intramuskularno (30 mikrogramov na teden).
In the active-controlled, randomised, double-blind, multicenter, non-inferiority trial of MabThera in granulomatosis with polyangiitis and microscopic polyangiitis, 24% of patients in the MabThera group (single course) and 23% of patients in the cyclophosphamide group developed CTC grade 3 or greater neutropenia.
V randomizirani, dvojno slepi, z zdravilno učinkovino kontrolirani multicentrični študiji neinferiornosti zdravila MabThera pri granulomatozi s poliangiitisom in mikroskopskem poliangiitisu se je nevtropenija, ki je bila 3. stopnje ali več po CTC, pojavila pri 24 % prejemnikov zdravila MabThera (en cikel) in pri 23 % prejemnikov ciklofosfamida.
In the acute conditions listed, Jentadueto should be temporarily discontinued.
Ob navedenih akutnih stanjih je treba začasno prekiniti zdravljenje z zdravilom Jentadueto.
In the add-on study with interferon beta-1a, the risk of disability getting worse and the number of relapses were reduced, but the way the study was designed did not allow the clear identification of whether these results were due to Tysabri only or to the combination.
V dodatni študiji z interferonom beta-1a sta bila manjša tveganje za poslabšanje prizadetosti in število recidivov, vendar pa zaradi zasnove študije ni bilo mogoče jasno opredeliti, ali so ti rezultati posledica zdravila Tysabri samega ali kombinacije.
In the additional phase 3 CONFIRMS study, for which results became available after the marketing authorisation for ADENURIC was first issued, the primary efficacy endpoint was the proportion of patients whose serum urate level was < 6.0 mg/dL at the final visit.
V dodatni študiji 3. faze CONFIRMS, za katero so bili rezultati na voljo po prvi pridobitvi dovoljenja za promet z zdravilom ADENURIC, je bil primarni opazovani dogodek učinkovitosti delež bolnikov, pri katerih je bil nivo sečne kisline v serumu na končnem pregledu < 6,0 mg/dl.
In the additional studies, once- and twice-daily Sprycel had similar rates of effectiveness, but the once-daily dose caused fewer side effects.
V dodatnih študijah so ugotovili, da sta enkrat dnevno in dvakrat dnevno vzeti odmerek podobno učinkovita, vendar pa enkrat dnevno vzeti odmerek povzroči manj neželenih učinkov.
In the additional study of Cimzia used on its own, more patients who received Cimzia achieved 20% reductions compared with those who received placebo.
V dodatni študiji zdravila Cimzia, uporabljenega kot samostojno zdravilo, je do 20-odstotnega zmanjšanja prišlo pri večjem številu bolnikov, ki so prejemali zdravilo Cimzia, kot pri tistih, ki so prejemali placebo.
In the additional study, more than half of the patients who could not be treated with deferoxamine had responded to treatment with Exjade after a year, including patients aged between 2 and 5 years.
V dodatni študiji se je več kot polovica bolnikov, ki ni mogla prejemati deferoksamina, po enem letu odzvala na zdravljenje z zdravilom Exjade, vključno z bolniki, starimi od dveh do pet let.
In the additional study, patients reported that they were ‘satisfied’ or ‘very satisfied’ with PecFent treatment for around 90% of breakthrough pain episodes.
V dodatni študiji so bolniki poročali, da so „zadovoljni“ ali „zelo zadovoljni“ z zdravljenjem z zdravilom PecFent pri približno 90 % epizod prebijajoče bolečine.
In the adjuvant setting, Glivec was investigated in a multicentre, double-blind, long-term, placebo- controlled phase III study (Z9001) involving 773 patients.
V okviru adjuvantnega zdravljenja so zdravilo Glivec raziskovali v multicentrični, dvojno slepi, dolgoročni, s placebom kontrolirani študiji faze III (Z9001), ki je vključevala 773 bolnikov.
In the adjuvant treatment of operable node-positive and node-negative breast cancer, the recommended dose of docetaxel is 75 mg/m2 administered 1-hour after doxorubicin 50 mg/m2 and cyclophosphamide 500 mg/m2 every 3 weeks for 6 cycles (TAC regimen) (see also Dose adjustments during treatment).
Pri dopolnilnem zdravljenju operabilnega raka dojke s pozitivnimi bezgavkami in negativnimi bezgavkami je priporočeni odmerek docetaksela 75 mg/m2, apliciran eno uro po doksorubicinu 50 mg/m2 in ciklofosfamidu 500 mg/m2 vsake tri tedne po 6 ciklusov (TAC režim) (glejte tudi Prilagajanje odmerka med zdravljenjem).
In the adjuvant treatment of operable node-positive and node-negative breast cancer, the recommended dose of docetaxel is 75 mg/m2 administered 1-hour after doxorubicin 50 mg/m2 and cyclophosphamide 500 mg/m2 every 3 weeks for 6 cycles (TAC regimen) (see also Dose adjustments during treatment).
Pri dopolnilnem zdravljenju operabilnega raka dojke s pozitivnimi bezgavkami in negativnimi bezgavkami je priporočeni odmerek docetaksela 75 mg/m2, apliciran eno uro po doksorubicinu 50 mg/m2 in ciklofosfamidu 500 mg/m2 vsake tri tedne v 6 ciklusih (TAC režim) (glejte tudi Prilagajanje odmerka med zdravljenjem).
In the adjuvant treatment of operable node-positive and node-negative breast cancer, the recommended dose of docetaxel is 75 mg/m2 administered 1-hour after doxorubicin 50 mg/m2 and cyclophosphamide 500 mg/m2 every 3 weeks for 6 cycles (TAC regimen) (see also Dose adjustments during treatment).
Pri dopolnilnem zdravljenju operabilnega raka dojke s pozitivnimi in negativnimi bezgavkami je priporočeni odmerek docetaksela 75 mg/m2, apliciran eno uro po doksorubicinu 50 mg/m2 in ciklofosfamidu 500 mg/m2 vsake 3 tedne po 6 ciklov (TAC režim) (glejte tudi Prilagajanje odmerka med zdravljenjem).
In the adjuvant treatment setting, Herceptin was investigated in 4 large multicentre, randomised, trials.
Pri adjuvantnem zdravljenju so zdravilo Herceptin proučevali v 4 obsežnih, multicentričnih, randomiziranih preskušanjih:
In the adolescent (13-17 years) schizophrenia population with aripiprazole exposure of 5 to 30 mg up to 72 months, incidence of low serum prolactin levels in females (< 3 ng/ml) and males (< 2 ng/ml) was 25.6% and 45.0%, respectively.
Pri populaciji mladostnikov (starosti od 13 do 17 let) s shizofrenijo, ki so največ 72 mesecev izpostavljeni apriprazolu 5 do 30 mg, je bila pojavnost nizkih vrednosti prolaktina v serumu pri ženskah (< 3 ng/ml) 25,6 % in pri moških (< 2 ng/ml) 45,0 %.
In the adolescent study, bactericidal responses following two doses of Bexsero were stratified by baseline hSBA less than 1:4 or equal to or greater than 1:4.
V študiji pri mladostnikih so baktericidne odzive po dveh odmerkih cepiva Bexsero stratificirali po izhodiščnem rezultatu hSBA manj od 1:4 ali enako ali več od 1:4.
In the AFFIRM trial, six patients (0.8%) experienced a seizure out of 800 post-chemotherapy patients treated with a daily dose of 160 mg enzalutamide, whereas no seizures occurred in patients receiving placebo.
V preskušanju AFFIRM so se konvulzije pojavile pri šestih (0,8 %) od 800 bolnikih po kemoterapiji, ki so prejemali dnevni odmerek 160 mg enzalutamida; pri prejemnikih placeba konvulzij ni bilo.
In the aflibercept treatment group (n = 224) at week 52, this treatment regimen resulted in patients receiving a mean of 9.2 injections, which is similar to the administered number of doses in the Eylea 2Q8 group in VIVIDDME and VISTADME, while overall efficacy of the aflibercept treatment group in Protocol T was comparable to the Eylea 2Q8 group in VIVIDDME and VISTADME.
V skupini, ki je bila zdravljena z afliberceptom (N = 224) v 52. tednu, so bolniki po tem režimu zdravljenja prejeli povprečno 9,2 injekciji, kar je bilo podobno prejetemu številu odmerkov v skupini Eylea 2Q8 v VIVIDDME in VISTADME, medtem ko je bila učinkovitost v skupini, zdravljeni z afliberceptom v protokolu T primerljiva s skupino Eylea 2Q8 v VIVIDDME in VISTADME.
In the age groups 1 months to 6 years, body weight-adjusted plasma clearance appeared higher but decreased in older children.
V starostnih skupinah 1 mesec do 6 let je bil plazemski očistek, prilagojen na telesno maso, večji, vendar se je zmanjšal pri starejših otrocih.
In the age groups 3 to < 12 years (n=36) and 12 to <18 years (n=26), mean IOP reduction at Week 12 in the travoprost group was similar to that in the timolol group.
V starostnih skupinah od 3 let do < 12 let (n=36) in od 12 let do < 18 let (n=26) je bila v skupini, ki je prejemala travoprost, srednja vrednost znižanja očesnega tlaka v 12. tednu podobna kot v skupini, ki je prejemala timolol.
In the All ACS population, prasugrel was associated with a lower incidence of CV death, non-fatal MI, or non-fatal stroke compared to clopidogrel, regardless of baseline characteristics such as age, sex, body weight, geographical region, use of GPIIb/IIIa inhibitors, and stent type.
V celotni ACS populaciji, je bil prasugrel povezan z nižjo incidenco CV smrti, ne-smrtnega MI ali ne-smrtne možganske kapi, v primerjavi s klopidogrelom, neodvisno od osnovnih značilnosti, kot so starost, spol, telesna masa, geografsko področje, uporaba zaviralcev GPIIb/IIIa in tip žilne opornice.
In the all- randomised population, capecitabine was shown to be superior to 5-FU/LV for disease-free survival (hazard ratio 0.849; 95% CI 0.739-0.976; p = 0.0212), as well as for overall survival (hazard ratio 0.828; 95% CI 0.705-0.971; p = 0.0203).
V celotni randomizirani populaciji je bil kapecitabin superioren v primerjavi s 5-FU/LV v preživetju brez bolezni (razmerje ogroženosti 0,849; 95-% interval zaupanja 0,739−0,976; p = 0,0212), kot tudi v celokupnem preživetju (razmerje ogroženosti 0,828; 95-% interval zaupanja 0,705−0,971; p = 0,0203).
In the all- randomised population, capecitabine was shown to be superior to 5FU/LV for disease-free survival (hazard ratio 0.849; 95% CI 0.739 - 0.976; p = 0.0212), as well as for overall survival (hazard ratio 0.828; 95% CI 0.705 - 0.971; p = 0.0203).
V celotni randomizirani populaciji je bil kapecitabin superioren v primerjavi s 5-FU/LV v preživetju brez bolezni (razmerje ogroženosti 0,849; 95-% interval zaupanja 0,739−0,976; p = 0,0212), kot tudi v celokupnem preživetju (razmerje ogroženosti 0,828; 95-% interval zaupanja 0,705−0,971; p = 0,0203).
In the all-randomised population, capecitabine was shown to be superior to 5-FU/LV for disease-free survival (hazard ratio 0.849; 95% CI 0.739 - 0.976; p = 0.0212), as well as for overall survival (hazard ratio 0.828; 95% CI 0.705 - 0.971; p = 0.0203).
V celotni randomizirani populaciji je bil kapecitabin superioren v primerjavi s 5-FU/LV v preživetju brez bolezni (razmerje ogroženosti 0,849; 95-% interval zaupanja 0,739−0,976; p = 0,0212), kot tudi v celokupnem preživetju (razmerje ogroženosti 0,828; 95-% interval zaupanja 0,705−0,971; p = 0,0203).
In the all-randomised population, capecitabine was shown to be superior to 5FU/LV for disease-free survival (hazard ratio 0.849; 95% CI 0.739 - 0.976; p = 0.0212), as well as for overall survival (hazard ratio 0.828; 95% CI 0.705 - 0.971; p = 0.0203).
V celotni randomizirani populaciji je bil kapecitabin superioren v primerjavi s 5-FU/LV v preživetju brez bolezni (razmerje ogroženosti 0,849; 95-% interval zaupanja 0,739−0,976; p = 0,0212), kot tudi v celokupnem preživetju (razmerje ogroženosti 0,828; 95-% interval zaupanja 0,705−0,971; p = 0,0203).